BIOLASE Adds Two New Independent Directors to Its Board

BIOLASE Adds Two New Independent Directors to Its Board 
Medical Device and Robotics Visionary Frederic Moll, M.D., and
Healthcare Banker & Chief Financial Officer Erin Enright to Join
Board of Directors 
IRVINE, CA -- (Marketwired) -- 06/10/13 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, announced today that, its board of directors (the "Board")
has increased its size from four to six members and, effective June
7, 2013, appointed Frederic H. Moll, M.D. and Erin S. Enright to the
Board. Dr. Moll and Ms. Enright were each determined to be
independent under the Nasdaq Listing Standards by the Company's Board
and met the requirements for committee assignments as set forth in
the respective committee charters.  
Frederic Moll, M.D., is Chairman and Chief Executive Officer of Auris
Surgical Robotics, Inc., the fourth surgical robotics company he has
founded. In 1995, Dr. Moll co-founded Intuitive Surgical, Inc.
(NASDAQ: ISRG), the world leader in surgical robotics. He served as
Intuitive's CEO through 1996 and a Director through 2004. Many credit
Dr. Moll with creating the surgical robotics industry. Dr. Moll has
been appointed to serve as a member of the Compensation Committee of
the Board. 
"I'm excited to be joining the BIOLASE(R) Board because the
tissue-cutting capabilities of the WaterLase(R) could make it a
game-changer in medical and surgical specialties far afield from the
dental industry in which it is currently known and valued," said Fred
Moll. 
Prior to Intuitive Surgical, Inc., Dr. Moll founded Endotherapeutics,
which was acquired by U.S. Surgical in 1992. He co-founded Origin
Medsystems, Inc., which was also acquired in 1992 by Eli Lilly and
later became an operating company in Guidant Corporation. Dr. Moll
served as medical director of Guidant's surgical device division from
1992 to 1995. Before co-founding Origin Medsystems, Dr. Moll invented
the safety trocar, which many experts believe created modern general
laparoscopic surgery. He also co-founded the intravascular robotics
company, Hansen Medical, Inc. and is a Director of the leading
hard-tissue orthopedics robotics company, MAKO Surgical Corporation. 
Erin Enright is a medical device executive, 
banker and attorney now
serving as the President of Lee Medical in Plainsboro, New Jersey, a
manufacturer of Lee-Lok(R) bone marrow needles. She is also the
managing director of Prettybrook Partners, which she operates with
her partner, Stuart Essig, former CEO of Integra Lifesciences
(NASDAQ: IART), a former board member of Zimmer Holdings, Inc. (NYSE:
ZMH), and a current board member of St. Jude Medical, Inc. (NYSE:
STJ). Ms. Enright is also a Founding Member and Director of
TigerLabs, a Princeton-based fund and technology accelerator. Ms.
Enright has been appointed to serve as a member of the Audit
Committee of the Board. 
"I believe there is a significant need for the hard tissue cutting
capabilities of the WaterLase in orthopedics, an application in which
the Company recently received an important FDA clearance," said Ms.
Enright. She also noted that... "with the variety of bone and
cartilage cutting, shaving and drilling procedures currently
performed with a rotating drill bit, I believe that there is a
significant opportunity for BIOLASE's WaterLase technology to become
used regularly in the orthopedic operating room." 
"We are extremely pleased with the addition of Fred and Erin to our
Board of Directors," said Federico Pignatelli, Chairman and Chief
Executive Officer. "Their experience and vision will be an invaluable
asset to the Board as it strategically guides the Company forward
into the next level of execution in our core laser dental leadership
and to also project our unique laser technologies into new medical
markets and opportunities. This is an exciting time for the employees
and stakeholders of BIOLASE." 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners; products
that are focused on technologies that advance the practice of
dentistry and medicine. The Company's proprietary laser products
incorporate over 350 patented and patent-pending technologies
designed to provide biologically clinically superior performance with
less pain and faster recovery times. Its imaginative products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications, and a full line of dental imaging equipment. BIOLASE
has sold more than 22,500 lasers. Other laser products under
development address ophthalmology and other medical and consumer
markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolaseinc, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, LinkedIn at
www.linkedin.com/company/biolase, Instagram at
www.instagram.com/biolaseinc and YouTube at
www.youtube.com/biolasevideos.  
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
Inc. 
For further information, please contact: 
Michael Porter 
Porter, LeVay & Rose, Inc. 
212-564-4700